Literature DB >> 20847207

Immune rage against MAGE unleashed.

Jeffrey J Molldrem1, Gheath Alatrash.   

Abstract

Year:  2010        PMID： 20847207      PMCID： PMC3173983          DOI： 10.1182/blood-2010-06-292912

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

1.  Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

Authors:  Oliver Goodyear; Angelo Agathanggelou; Igor Novitzky-Basso; Shamyla Siddique; Tina McSkeane; Gordon Ryan; Paresh Vyas; Jamie Cavenagh; Tanja Stankovic; Paul Moss; Charles Craddock
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

2.  DNA methylation in the treatment of hematologic malignancies.

Authors:  Jean-Pierre Issa
Journal:  Clin Adv Hematol Oncol       Date:  2005-09

Review 3.  Leukaemia stem cells and the evolution of cancer-stem-cell research.

Authors:  Brian J P Huntly; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 4.  Aire.

Authors:  Diane Mathis; Christophe Benoist
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

5.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.

Authors:  R Szydlo; J M Goldman; J P Klein; R P Gale; R C Ash; F H Bach; B A Bradley; J T Casper; N Flomenberg; J L Gajewski; E Gluckman; P J Henslee-Downey; J M Hows; N Jacobsen; H J Kolb; B Lowenberg; T Masaoka; P A Rowlings; P M Sondel; D W van Bekkum; J J van Rood; M R Vowels; M J Zhang; M M Horowitz
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

6.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.

Authors:  J J Molldrem; P P Lee; C Wang; K Felio; H M Kantarjian; R E Champlin; M M Davis
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

7.  Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

Authors:  Jeffrey J Molldrem; Peter P Lee; Shreya Kant; Eric Wieder; Weidong Jiang; Sijie Lu; Changqing Wang; Mark M Davis
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

9.  Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.

Authors:  A J Barrett; M M Horowitz; B H Pollock; M J Zhang; M M Bortin; G R Buchanan; B M Camitta; J Ochs; J Graham-Pole; P A Rowlings
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

10.  Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.

Authors:  Gautam Borthakur; Samih El Ahdab; Farhad Ravandi; Stefan Faderl; Alessandra Ferrajoli; Beth Newman; Jean-Pierre Issa; Hagop Kantarjian
Journal:  Leuk Lymphoma       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.